Lineage, Inc. Common Stock (LINE)vsSabra Healthcare REIT Inc (SBRA)
LINE
Lineage, Inc. Common Stock
$37.75
+0.96%
REAL ESTATE · Cap: $9.50B
SBRA
Sabra Healthcare REIT Inc
$20.52
-1.49%
REAL ESTATE · Cap: $5.31B
Smart Verdict
WallStSmart Research — data-driven comparison
Lineage, Inc. Common Stock generates 522% more annual revenue ($5.37B vs $863.77M). SBRA leads profitability with a 7.6% profit margin vs -3.1%. SBRA earns a higher WallStSmart Score of 43/100 (D).
LINE
Avoid35
out of 100
Grade: F
SBRA
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LINE.
Margin of Safety
+84.4%
Fair Value
$125.35
Current Price
$20.52
$104.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Reasonable price relative to book value
Revenue surging 25.3% year-over-year
Areas to Watch
0.8% revenue growth
0.0% earnings growth
Operating margin of 3.7%
Elevated debt levels
ROE of 5.6% — below average capital efficiency
7.6% margin — thin
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : SBRA
The strongest argument for SBRA centers on Price/Book, Revenue Growth. Revenue growth of 25.3% demonstrates continued momentum.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : SBRA
The primary concerns for SBRA are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 80.0x leaves little room for execution misses.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while SBRA is a growth play — different risk/reward profiles.
LINE carries more volatility with a beta of 0.88 — expect wider price swings.
SBRA is growing revenue faster at 25.3% — sustainability is the question.
LINE generates stronger free cash flow (186M), providing more financial flexibility.
Bottom Line
SBRA scores higher overall (43/100 vs 35/100) and 25.3% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.
Visit Website →Sabra Healthcare REIT Inc
REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA
As of September 30, 2020, Sabra's investment portfolio included 425 real estate properties held for investment (consisting of (i) 287 skilled nursing / transitional care facilities, (ii) 64 senior housing communities (?
Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?